Global Biopharmaceutical Company UCB Expands Real Estate Services Relationship With JLL

LONDON, UNITED KINGDOM--(Marketwired - November 11, 2014) -

Brussels-based biopharmaceutical company UCB has renewed a three year global real estate services agreement with JLL (NYSE: JLL).

The agreement spans 40 countries and expands on a mandate awarded in 2011 where JLL was appointed to provide lease administration, transaction management and real estate advisory services. New services added include financial management and project and development services (P&DS). Tétris Design & Build, JLL’s specialist design, fit-out and refurbishment team have also been appointed to work on multiple occupier projects.

“Since 2011 when this client relationship started, we have focused on providing the most efficient corporate solutions framework for UCB’s global real estate portfolio. We have already generated EUR 9.5 million in cost savings across Japan, France, Spain, Portugal, The Netherlands and Italy. The largest individual project undertaken to date by JLL was the relocation of UCB’s Japanese 2,650 m² offices in Tokyo. The newly extended contract scope means that we will further build on this and continuously enhance real estate solutions supported by robust project management services,” said Eric Orban, UCB Global Client Manager, JLL Corporate Solutions.

“JLL has helped us gain clarity across our global real estate portfolio. This knowledge has permitted us to anticipate lease events and start taking sound and strategic decisions in line with our future business needs. Comparing our various local situations with relevant market intelligence has given us an unprecedented edge in our real estate portfolio management,” said Jean-Christophe Donck, Vice-President Site Facilities & Workplace Development, UCB.

Vincent Lottefier, Global Director and CEO Corporate Solutions, Europe, Middle East & Africa for JLL, said, “This extended contract epitomises the trend for European headquartered multinational corporates to task a specialist adviser to help them control and manage their commercial real estate across the globe. The client benefit is clear -- increased productivity, consistent service and substantial cost savings. We are excited to have been re-appointed to work with UCB and look forward to supporting their global strategic and operational activities.”

JLL Corporate Solutions has recently been appointed by multiple global financial services, oil and gas and professional companies. Existing pharmaceutical sector clients include Pfizer, GSK, AstraZeneca and Sanofi.

Headquartered in Brussels, Belgium, UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8,500 people in approximately 40 countries, the company generated revenue of EUR 3.4 billion in 2013. UCB is listed on Euronext Brussels (EURONEXT BRUSSELS: UCB).

About JLL
JLL (NYSE: JLL) is a professional services and investment management firm offering specialized real estate services to clients seeking increased value by owning, occupying and investing in real estate. With annual fee revenue of $4.0 billion and gross revenue of $4.5 billion, JLL has more than 200 corporate offices, operates in 75 countries and has a global workforce of approximately 53,000. On behalf of its clients, the firm provides management and real estate outsourcing services for a property portfolio of 3.0 billion square feet, or 280.0 million square meters, and completed $99.0 billion in sales, acquisitions and finance transactions in 2013. Its investment management business, LaSalle Investment Management, has $50.0 billion of real estate assets under management. JLL is the brand name, and a registered trademark, of Jones Lang LaSalle Incorporated. For further information, visit www.jll.com.